Regenerex Pharma, Inc. financial data

Symbol
RGPX on OTC
Location
5348 Vegas Drive, Suite 177, Las Vegas, NV
State of incorporation
NV
Fiscal year end
March 31
Former names
PEPTIDE TECHNOLOGIES, INC. (to 12/22/2021), Eternelle Skincare Products Inc. (to 2/8/2018), CREENERGY Corp (to 10/6/2011), ONLINE ORIGINALS, INC (to 7/19/2010)
Latest financial report
10-Q - Q4 2024 - Feb 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.04 % -96.8%
Debt-to-equity -115 % +10.7%
Return On Equity 31 % -77.2%
Return On Assets -203 % +56.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 278M shares +0.17%
Common Stock, Shares, Outstanding 278M shares +0.19%
Entity Public Float 0 USD
Common Stock, Value, Issued 278K USD +0.19%
Weighted Average Number of Shares Outstanding, Basic 278M shares +0.19%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 17.4K USD
Selling and Marketing Expense 3K USD
General and Administrative Expense 1.09M USD +33.6%
Operating Income (Loss) -1.1M USD +65.6%
Nonoperating Income (Expense) -305K USD -265%
Net Income (Loss) Attributable to Parent -1.41M USD +57.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 338 USD -95.7%
Assets, Current 988 USD -89.4%
Property, Plant and Equipment, Net 5.23K USD
Operating Lease, Right-of-Use Asset 641K USD -23.2%
Assets 647K USD -24.1%
Accounts Payable, Current 185K USD +134%
Employee-related Liabilities, Current 803K USD +93.4%
Accrued Liabilities, Current 142K USD +70.5%
Liabilities, Current 5.16M USD +45%
Operating Lease, Liability, Noncurrent 541K USD -25.3%
Liabilities 5.7M USD +20.6%
Retained Earnings (Accumulated Deficit) -6.73M USD -26.5%
Stockholders' Equity Attributable to Parent -5.05M USD -30.4%
Liabilities and Equity 647K USD -24.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.3K USD +54.4%
Net Cash Provided by (Used in) Financing Activities 55K USD -71.3%
Net Cash Provided by (Used in) Investing Activities -3.63K USD
Common Stock, Shares Authorized 675M shares 0%
Common Stock, Shares, Issued 278M shares +0.19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -372 USD -101%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 338 USD -95.7%
Deferred Tax Assets, Valuation Allowance 1.05M USD +190%
Depreciation 1.14K USD +37.7%
Operating Lease, Liability, Current 177K USD +16.7%
Deferred Tax Assets, Operating Loss Carryforwards 464K USD +34.2%
Additional Paid in Capital 1.4M USD +19.8%
Amortization of Intangible Assets 2.04K USD -18.4%
Interest Expense 338K USD +345%